|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash and cash equivalents | |||||||||
| Financial assets | |||||||||
| Accounts receivable and other | |||||||||
| Inventory | |||||||||
| Assets classified as held for sale | |||||||||
| Current assets | |||||||||
| Property, plant and equipment | |||||||||
| Intangible assets | |||||||||
| Investments in associates and joint ventures | |||||||||
| Investment properties | |||||||||
| Goodwill | |||||||||
| Other assets | |||||||||
| Deferred income tax asset | |||||||||
| Total assets | |||||||||
| Liabilities and Partnership Capital | |||||||||
| Liabilities | |||||||||
| Accounts payable and other | |||||||||
| Corporate borrowings | |||||||||
| Non-recourse borrowings | |||||||||
| Financial liabilities | |||||||||
| Liabilities directly associated with assets classified as held for sale | |||||||||
| Current liabilities | |||||||||
| Other liabilities | |||||||||
| Deferred income tax liability | |||||||||
| Preferred shares | |||||||||
| Total liabilities associated with assets held for sale | |||||||||
| Partnership capital | |||||||||
| Limited partners | |||||||||
| General partner | |||||||||
| Non-controlling interest attributable to: | |||||||||
| Redeemable Partnership Units held by Brookfield | |||||||||
| BIPC exchangeable shares and class A.2 exchangeable shares | |||||||||
| Exchangeable units | |||||||||
| Perpetual subordinated notes | |||||||||
| Interest of others in operating subsidiaries | |||||||||
| Preferred unitholders | |||||||||
| Total partnership capital | |||||||||
| Total liabilities and partnership capital |
Loading...
